摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 3-(4-chlorobenzyl)-2,4-dioxoquinazoline-7-carboxylate | 917889-36-2

中文名称
——
中文别名
——
英文名称
methyl 3-(4-chlorobenzyl)-2,4-dioxoquinazoline-7-carboxylate
英文别名
3-(4-chloro-benzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-7-carboxylic acid methyl ester;methyl 3-[(4-chlorophenyl)methyl]-2,4-dioxo-1H-quinazoline-7-carboxylate
methyl 3-(4-chlorobenzyl)-2,4-dioxoquinazoline-7-carboxylate化学式
CAS
917889-36-2
化学式
C17H13ClN2O4
mdl
——
分子量
344.754
InChiKey
MFJIOYINNXROGW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    24
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    75.7
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    methyl 3-(4-chlorobenzyl)-2,4-dioxoquinazoline-7-carboxylatesodium hydroxide 作用下, 以 1,4-二氧六环 为溶剂, 反应 1.0h, 以91%的产率得到3-(4-chlorobenzyl)-2,4-dioxoquinazoline-7-carboxylic acid
    参考文献:
    名称:
    Novel T-type calcium channel blockers: Dioxoquinazoline carboxamide derivatives
    摘要:
    T-type calcium channel is one of therapeutic targets for the treatment of cardiovascular diseases and neuropathic pains. Since the withdrawal of mibefradil, a T-type calcium channel blocker, there have been a lot of efforts to develop T-type calcium channel blockers. A small molecule library of dioxoquinazoline carboxamide derivatives containing 155 compounds was designed, synthesized, and biologically evaluated for T-type calcium channel blocking activity. Among those compounds synthesized, the compound In shows the most potent T-type calcium current blocking activity with an IC50 value of 1.52 mu M, which is comparable to that of mibefradil. (c) 2006 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2006.09.051
  • 作为产物:
    描述:
    2-氨基对苯二甲酸二甲酯4-氯苯甲酯异氰酸三乙胺 作用下, 以 1,4-二氧六环 为溶剂, 反应 72.0h, 以41%的产率得到methyl 3-(4-chlorobenzyl)-2,4-dioxoquinazoline-7-carboxylate
    参考文献:
    名称:
    Novel T-type calcium channel blockers: Dioxoquinazoline carboxamide derivatives
    摘要:
    T-type calcium channel is one of therapeutic targets for the treatment of cardiovascular diseases and neuropathic pains. Since the withdrawal of mibefradil, a T-type calcium channel blocker, there have been a lot of efforts to develop T-type calcium channel blockers. A small molecule library of dioxoquinazoline carboxamide derivatives containing 155 compounds was designed, synthesized, and biologically evaluated for T-type calcium channel blocking activity. Among those compounds synthesized, the compound In shows the most potent T-type calcium current blocking activity with an IC50 value of 1.52 mu M, which is comparable to that of mibefradil. (c) 2006 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2006.09.051
点击查看最新优质反应信息

文献信息

  • PHARMACEUTICAL COMPOSITIONS CONTAINING QUINAZOLINE DERIVATIVES FOR TREATING AS SEROTONIN RECEPTOR ANTAGONIST
    申请人:NAM Ghil Soo
    公开号:US20090054433A1
    公开(公告)日:2009-02-26
    The present invention relates to a pharmaceutical composition containing one or more quinazoline compounds as an active ingredient, which has antagonistic activity against serotonin 5-HT 3 A and is effective for the prevention and treatment of central nervous system (CNS) diseases, including emesis, nausea, alcoholism, drug abuse, depression, compulsive neurosis, anxiety, seizure, Alzheimer's disease, Parkinson's disease, Huntington's chorea, psychosis, schizophrenia, suicidal tendency, sleep disorder, appetite disorder and migraine.
    本发明涉及一种药物组合物,其包含一种或多种喹唑啉化合物作为活性成分,具有对5-HT3A血清素拮抗活性,并且对预防和治疗中枢神经系统(CNS)疾病有效,包括呕吐、恶心、酗酒、药物滥用、抑郁症、强迫神经症、焦虑、癫痫、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、精神病、精神分裂症、自杀倾向、睡眠障碍、食欲障碍和偏头痛。
  • US8748422B2
    申请人:——
    公开号:US8748422B2
    公开(公告)日:2014-06-10
  • Novel T-type calcium channel blockers: Dioxoquinazoline carboxamide derivatives
    作者:Mi Na Jo、Hee Jeong Seo、Yoonji Kim、Seon Hee Seo、Hyewhon Rhim、Yong Seo Cho、Joo Hwan Cha、Hun Yeong Koh、Hyunah Choo、Ae Nim Pae
    DOI:10.1016/j.bmc.2006.09.051
    日期:2007.1.1
    T-type calcium channel is one of therapeutic targets for the treatment of cardiovascular diseases and neuropathic pains. Since the withdrawal of mibefradil, a T-type calcium channel blocker, there have been a lot of efforts to develop T-type calcium channel blockers. A small molecule library of dioxoquinazoline carboxamide derivatives containing 155 compounds was designed, synthesized, and biologically evaluated for T-type calcium channel blocking activity. Among those compounds synthesized, the compound In shows the most potent T-type calcium current blocking activity with an IC50 value of 1.52 mu M, which is comparable to that of mibefradil. (c) 2006 Elsevier Ltd. All rights reserved.
查看更多